Results 131 to 140 of about 107,466 (267)

GV1001, hTERT Peptide Fragment, Prevents 5-Fluorouracil-Induced Mucositis by Inhibiting Mitochondrial Damages. [PDF]

Cells
Beheshtian C, Chen W, Kim S, Jun A, Bae EB, Kim R, Kim S, Park NH.   +7 more
europepmc   +1 more source

Longitudinal changes in bleb morphology following the PAUL Glaucoma Implant visualized using ultrasonography

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate bleb morphology longitudinally using sonography following glaucoma drainage device (GDD) surgery. Methods Prospective observational cohort study conducted from January 2022 to March 2024, with follow‐up up to 12 months postoperatively. Bleb morphology, including superior and inferior bleb height, transverse and longitudinal
Constance Liegl, Benjamin Aretz, Leonie Bourauel, Pascal Schipper, Carolin Deubel, Lilli Joussen, Michael Petrak, Frank G. Holz, Raffael Liegl, Karl Mercieca   +9 more
wiley   +1 more source

Cyclodextrin-Based Nanocarriers for 5-Fluorouracil: Cholesteryl Modification Enhances Antitumor Activity Against Colorectal Cancer Cells. [PDF]

Int J Nanomedicine
Skonieczna B, Maliszewski B, Wasiluk N, Car H, Wilczewska AZ, Misiak P, Niemirowicz-Laskowska K.   +6 more
europepmc   +1 more source

Proliferative vitreoretinopathy: An integrative, multi‐pathway perspective on pathogenesis and therapy

Acta Ophthalmologica, EarlyView.
Abstract Proliferative vitreoretinopathy (PVR) remains the principal biological cause of failed retinal detachment repair. Classical pathogenic models centred on retinal pigment epithelium (RPE) dispersion, retinal injury responses or compartment‐restricted mechanisms do not fully explain the heterogeneity, biomechanical behaviour and clinical ...
Koen A. van Overdam, J. Sebag
wiley   +1 more source

Combinatorial effect of epirubicin and 5-fluorouracil in the treatment of temozolomide-resistant glioblastoma cells. [PDF]

Turk J Biol
Bayat M, Akman M, Kiliç T, Avşar T.
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

PTPRE promotes gastric cancer cell resistance to 5-fluorouracil by inhibiting ferroptosis via the Src/FAK/TRIB3 axis. [PDF]

PLoS One
Liu M, Liao X, Wang F, Jiao P, Wang Z.
europepmc   +1 more source

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

British Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen, Ines Bentahrour, Camille Guerin, Charles Dolladille, Angélique Da Silva, François Cherifi, Elise‐Marie Minoc, Pierre‐Marie Morice, Nicolas Jacquin, Christophe Le Tourneau, Joachim Alexandre, Ahmad Nehme, Etienne Bastien   +12 more
wiley   +1 more source

Uridine Triacetate for Severe Fluoropyrimidine Cardiotoxicity in a Patient With Thymidylate Synthase Gene Variants

JACC. CardioOncology, 2020
Inbar Raber, MD, Morgan B. Frazer, PharmD, BCOP, Jessica A. Zerillo, MD, MPH, Aarti Asnani, MD   +3 more
doaj   +1 more source

Factors influencing pharmacokinetics of 5-fluorouracil in cancer patients: a systematic review of population pharmacokinetic models. [PDF]

Eur J Clin Pharmacol
Suthahar T, Veerabhadrappa J, Munshi R, Anbu Raj E, Gota V, Ivaturi V, Mallayasamy S.   +6 more
europepmc   +1 more source